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Background: Major depressive disorder (MDD) is predominantly managed in primary care. However, primary
care providers (PCPs) may not consistently follow evidence-based treatment algorithms, leading to variable
patient management that can impact outcomes.
Methods: We retrospectively analyzed adult patients with MDD seen at Geisinger, an integrated health system.
Utilizing electronic health record (EHR) data, we classified patients as having MDD based on International
Classification of Disease (ICD)-9/10 codes or a Patient Health Questionnaire (PHQ)-9 score ≥5. Outcomes
assessed included time to first visit with a PCP or behavioral health specialist following diagnosis, antidepressant
medication switching, persistence, healthcare resource utilization (HRU), and treatment costs.
Results: Among the 38,321 patients with MDD managed in primary care in this study, significant delays between
diagnosis with antidepressant prescribing and follow-up PCP visits were observed. There was also considerable
variation in care following diagnosis. Overall, 34.9% of patients with an ICD-9/10 diagnosis of MDD and 41.3%
with a PHQ-9 score ≥15 switched antidepressants. An ICD-9/10 diagnosis, but not moderately severe to severe
depression, was associated with higher costs and HRU. More than 75% of patients with MDD discontinued an
tidepressant medication within 6 months.
Limitations: The study population was comparable with other real-world studies of MDD, but study limitations
include its retrospective nature and reliance on the accuracy of EHRs.
Conclusions: Management of patients with MDD in a primary care setting is variable. Addressing these gaps will
have important implications for ensuring optimal patient management, which may reduce HRU and treatment
medication costs, and improve treatment persistence.
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Association, 2019). This presents a challenging decision-making process
in a primary care setting, where patients often have comorbidities
(including other mental health conditions) that may be managed by
other providers, and can lead to a fragmented approach to care (Mosher
Henke, 2008; Gunn et al., 2012; Grazier et al., 2014). PCPs also face
other barriers to adequately treating depression once a diagnosis is
made, including patient reluctance to initiate treatment, lack of insur
ance reimbursement, inadequate experience and training in mental
health, and competing clinical demands. (Mosher Henke, 2008; Schu
mann et al., 2012; Grazier et al., 2014; Colorafi et al., 2017). Further
more, access to specialist mental health services and behavioral health
(BH) services that provide guideline-recommended psychotherapy (eg,
cognitive behavioral therapy, supportive therapy, psychodynamic
therapy, problem-solving therapy) may be limited (Mosher Henke,
2008; American Psychological Association, 2019). Therefore, under
standing the pathways of care followed and experiences of patients
diagnosed with depression in primary care is important for under
standing whether the expected benefits of screening translate into
improved outcomes for patients.
The aim of this study was to characterize the care of patients with
depression seen by PCPs in an integrated health system. This includes
assessments of follow-up care received by patients after being diagnosed
with depression, treatment patterns, healthcare resource utilization
(HRU), and treatment persistence in an attempt to identify opportunities
for improvement in the care provided. In particular, the care of patients
with moderately severe and severe depression (PHQ-9 score ≥15) who
may require more intensive therapy and referral to specialist BH services
in addition to pharmacotherapy was investigated (American Psychiatric
Association, 2010).

Abbreviations
BH
behavioral health
BMI
body mass index
CCI
Charlson Comorbidity Index
CI
confidence interval
ED
emergency department
EHR
electronic health record
GERD
gastroesophageal reflux disease
GI
gastrointestinal
HRU
healthcare resource utilization
IBD
inflammatory bowel disease
IBS
irritable bowel syndrome
ICD-9
International Classification of Disease
IQR
interquartile range
NDRI
norepinephrine-dopamine reuptake inhibitor
PCPs
primary care providers
PHQ-9
Patient Health Questionnaire-9
SD
standard deviation
SNRI
serotonin-norepinephrine reuptake inhibitor
SSRI
selective serotonin reuptake inhibitor
USPSTF US Preventive Services Task Force
1. Introduction
Major depressive disorder (MDD) is a highly prevalent mental illness
and a leading cause of disability (National Institute of Mental Health,
2019). Every year, 17.3 million adults (7.1%) in the United States
experience at least 1 episode of major depression (National Institute of
Mental Health, 2019; Pilon et al., 2019), placing a considerable burden
on the healthcare system. Medical costs associated with MDD were
estimated to be $326.2 billion in 2018 (converted to 2020 US dollars)
(Greenberg et al., 2021). Despite its significant morbidity and cost, MDD
remains underdetected and underdiagnosed (Harman et al., 2006;
Unützer and Park, 2012).
Because depression is a leading cause of disability in the United
States, the US Preventive Services Task Force (USPSTF) recommends
that all adults be screened for depression in primary care to identify
patients requiring treatment, with the aim of reducing overall clinical
morbidity (Siu et al., 2016). A number of screening instruments are
recommended, including the Patient Health Questionnaire-9 (PHQ-9),
which includes 9 depression criteria from the Diagnostic and Statistical
Manual of Mental Disorders, Fourth Edition, and is designed to be
self-administered by patients (Savoy and O’Gurek, 2016; Siu et al.,
2016). Other options for screening instruments that can be used in a
primary care setting include the Hospital Anxiety and Depression Scale
and specialist assessments such as the Geriatric Depression Scale for
older adults and Edinburgh Postnatal Depression Scale for postpartum
and pregnant women (Savoy and O’Gurke, 2016; Siu et al., 2016).
Prior reports have indicated that two-thirds of visits to healthcare
providers by patients with MDD occur in a primary care setting (Har
man et al., 2006), although this may be an underestimate following the
strengthening of the USPSTF recommendation to screen for depression
in routine clinical practice (Siu et al., 2016). Therefore, primary care
providers (PCPs) shoulder a substantial burden with regard to the
diagnosis and initial management of depression.
Despite available guidelines from organizations such as the Amer
ican Psychiatric and American Psychological Associations (American
Psychiatric Association, 2010; American Psychological Association,
2019), MDD continues to be undertreated in the primary care setting,
with low treatment effectiveness and persistence reported (National
Institute of Mental Health, 2019; Unützer and Park, 2012). For example,
the American Psychological Association provides differing treatment
recommendations for depression, MDD (± medical or other complica
tions), subthreshold/minor depression (± cognitive impairment/de
mentia), and persistent depressive disorder (American Psychological

2. Methods
2.1. Data source
Geisinger (Danville, PA, USA) is an integrated healthcare system
currently serving approximately 4.2 million people. Geisinger possesses
an extensive electronic health record (EHR) database comprising data
from all patients across ambulatory and inpatient sites of care. We uti
lized this EHR data for this study as well as insurance claims data from
the Geisinger Health Plan.
2.2. Study design and patient population
We included adult patients seen within the Geisinger system who had
a new diagnosis of MDD between January 1, 2012, and June 30, 2017.
Patients had to be aged ≥18 years and enrolled in the Geisinger system
for at least 2 years prior to an initial diagnosis of MDD and have
completed an outpatient, emergency department (ED) to inpatient, EDonly, or inpatient-only encounter.
An initial diagnosis of MDD was determined using International
Classification of Disease (ICD)-9/10 and PHQ-9 scores. ICD-9/10 di
agnoses were defined as follows: ICD-9 code of 296.20, 296.21, 296.22,
296.23, 296.24, 296.25, 296.26, 296.30, 296.31, 296.32, 296.33,
296.34, 296.35, 296.36, 300.4, or 311; or ICD-10 code of F32.0, F32.1,
F32.2, F32.3, F32.4, F32.5, F32.8, F32.9, F33.0, F33.1, F33.2, F33.3,
F33.41, F33.42, F33.9, or F34.1. PHQ-9 scores were grouped by degree
of severity, with 0 indicating “no depression present”; 1–4, “minimal or
no depression”; 5–9, “mild depression”; 10–14, “moderate depression”;
15–19, “moderately severe depression”; or ≥20, indicating “severe
depression” (Kroenke et al., 2001). Analyses of patients with
PHQ-9–defined depression included investigating the subset of patients
with a PHQ-9 score ≥15, representing moderately severe and severe
depression, who were expected to be treated with antidepressant and
behavioral therapy (Kroenke et al., 2001; American Psychiatric Associ
ation, 2010). Patients without an ICD-9/10 diagnosis of MDD required a
PHQ-9 total score of ≥5 to be eligible for the study.
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were obese (body mass index [BMI] 30.0–39.9 kg/m2) or morbidly
obese (BMI ≥40 kg/m2), and mean BMI was comparable between pa
tients with ICD-9/10 and PHQ-9 ≥15 diagnoses.
Comorbidities were common in both the ICD-9/10 and PHQ-9 ≥15
groups (median [interquartile range (IQR)] of 3 [1–5] and 3 [2–6],
respectively) (Table 1; Table 2). The most common comorbidities were
metabolic disorders (eg, hypertension, hyperlipidemia, type 2 diabetes);
psychiatric disorders (eg, anxiety disorder, alcohol/substance use dis
order, sleep disorder); and gastrointestinal (GI) disorders (eg, gastro
esophageal reflux disease, inflammatory bowel disease, or irritable
bowel syndrome). The prevalence of anxiety, substance/alcohol use
disorders, GI disorders, sleeping disorders, and asthma was higher in
patients with a PHQ-9 score ≥15 versus an ICD-9/10 diagnosis
(Table 2).

The index date was defined as the first date of diagnosis of incident
depression in the study period. To be eligible, patients needed a mini
mum of 12 months of follow-up data following the index date. Patients
with bipolar disorder, schizophrenia or schizoaffective disorder, or brief
psychotic disorder were excluded from the study. Patients who were
pregnant during the study period—defined as such during the study
period or 9 months prior (April 1, 2011, to June 30, 2017)—were also
excluded.
2.3. Outcomes
We evaluated several outcomes, including the time from the index
date to first PCP and BH visit, antidepressant medication switching, HRU
in the first year after the index date, cost, and antidepressant persistence.
Antidepressant persistence was defined as the time from the medication
start date to the stop date in the patient’s EHR, end of follow-up, or a gap
of up to 30 days in continuous access to medication. In the event of a 30day gap in medication access, the stop date was defined as the end of the
30-day gap.

3.2. Time to first primary care provider and behavioral health visit
The mean (standard deviation [SD]) delay between the time of initial
diagnosis and first postdiagnosis PCP visit was 124 (235) days for the
ICD-9/10 diagnosis group and 100–110 (135–150) days for the PHQ-9
diagnosis group (any severity) (Fig. 2A). Mean (SD) number of days to
first PCP visit following the first antidepressant prescription was 509
(460) days for an ICD-9/10 diagnosis and 485–578 (468–489) days for a
PHQ-9 diagnosis (Fig. 2B). The median times to first postdiagnosis visit
and first post–antidepressant prescription visit were significantly shorter
than the means for both groups, and the IQRs were wide (ICD-9/10:
median [IQR], 31 [10–116] days and 409 [76–833] days, respectively;
PHQ-9 [any severity]: median [IQR], 42–63 [16–137] days and
363–547 [41–960] days).
There was no clear association between PHQ-9 score at the time of
diagnosis and time to first visit after first antidepressant prescription.
Among patients who were referred to BH, male patients were seen
earlier than female patients (Supplementary Fig. 2). For patients
diagnosed with MDD who were referred to BH (n=3023; 7.9%),
advancing age, number of comorbidities at pre-index date, and an ICD9/10 diagnosis were associated with a significantly longer time to first
BH visit (Supplementary Fig. 2).

2.4. Statistical analysis
Study patient demographics were summarized using descriptive
statistics. Outcomes were analyzed using negative binomial regression,
gamma distribution, binary and ordinal logistic regression, or survival
analyses (Cox proportional hazards and Kaplan-Meier curves). All sta
tistical analyses were performed using SAS (version 9.4; SAS Institute,
Inc. Cary, NC, USA). Individual patients could be represented in both the
ICD-9/10 and PHQ-9 cohorts (Fig. 1).
3. Results
3.1. Baseline characteristics and demographics
We identified 38,321 eligible patients; 20,780 had an ICD-9/10
diagnosis of MDD and 20,808 patients had a PHQ-9 diagnosis (PHQ-9
score ≥5) of depression, with some patients included in both pop
ulations (Table 1; Supplementary Fig. 1). Of patients who had a PHQ-9
diagnosis, 6453 (31%) were considered to have moderate depression
(score 10–14), 5523 (26.5%) to have moderately severe depression
(score 15–19), and 3454 (16.6%) to have severe depression (score ≥20).
Patients with an ICD-9/10 diagnosis had a mean age of 55.0 years
compared with 48.1 years in the PHQ-9 ≥15 study population. Both the
ICD-9/10 and PHQ-9 ≥15 populations were predominantly female
(64.1% and 66.9%, respectively). Almost 50% of the patients with MDD

3.3. Medication switches
One-third of patients with an ICD-9/10 diagnosis (5014/14,371;
34.9%) switched antidepressant medication at least once during the
study period, with 18.8% of patients (2701/14,371) switching antide
pressant medication ≥3 times. However, 41.3% of all patients with a
PHQ-9 score ≥15 (2842/6885) switched antidepressant medication at
least once during the study period, although a similar percentage of
patients (1431/6885; 20.8%) switched antidepressant medication ≥3
times. Median (IQR) time to antidepressant medication switch was 556
(149–1107) days for patients with an ICD-9/10 diagnosis.
Smoking (current), number of prescribed medications, number of
pre-index comorbidities, an ICD-9/10 diagnosis, and a PHQ-9 score ≥15
were associated with a significantly higher likelihood of antidepressant
medication switching (Supplementary Fig. 3). In contrast, advancing
age, male sex, and increasing BMI (by kg/m2) were associated with a
significantly lower probability of antidepressant medication switching
(Supplementary Fig. 3).
3.4. Healthcare resource utilization and cost
An ICD-9/10 diagnosis of MDD was associated with an increase in
medication costs within 12 months (relative risk, 2.31; p<0.0001).
However, a PHQ-9 score ≥15 was associated with a decrease in medi
cation costs within 12 months (relative risk, 0.9030; p<0.001).
The number of all medications prescribed prior to index date and
pre-existing comorbidities at diagnosis were also associated with
increased medication costs during the first year (Supplementary Fig.

Fig. 1. Cohort distribution by ICD-9/10 diagnosis and PHQ-9 score. aPatients
with both an ICD-9/10 diagnosis and PHQ-9 score; bPHQ-9 0 represents an
actual score of 0 and not a missing value. ICD, International Classification of
Disease; PHQ-9, Patient Health Questionnaire-9.
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Table 1
Baseline characteristics and demographics.
PHQ-9 score
Characteristics

ICD-9/10 population
(n=20,780)

0 (n=3254)

1–4
(n=1837)

5–9
(n=5378)

10–14
(n=6453)

15–19
(n=5523)

≥20
(n=3454)

Age, years, mean (SD)
Age, group, years, n (%)
18–26
27–39
40–59
60þ
Sex, female, n (%)
Married, n (%)
Alcohol use, n (%)
Drug use, n (%)

55.0 (19.0)

56.3 (18.3)

55.5 (17.1)

54.4 (18.1)

51.2 (17.9)

48.2 (17.2)

47.1 (15.8)

1805 (8.7)
2999 (14.4)
7182 (34.6)
8794 (42.3)
13,325 (64.1)
7772 (37.4)
5654 (27.2)
692 (3.3)

279 (8.6)
392 (12.0)
1038 (31.9)
1545 (47.5)
2147 (66.0)
1448 (44.5)
957 (29.4)
59 (1.8)

109 (5.9)
250 (13.6)
730 (39.7)
748 (40.7)
1321 (71.9)
803 (43.7)
577 (31.4)
26 (1.4)

453 (8.4)
737 (13.7)
1977 (36.8)
2211 (41.1)
3205 (59.6)
2579 (48.0)
1686 (31.3)
79 (1.5)

684 (10.6)
1117 (17.3)
2493 (38.6)
2159 (33.5)
4095 (63.5)
2893 (44.8)
2014 (31.2)
125 (1.9)

677 (12.3)
1153 (20.9)
2266 (41.0)
1427 (25.8)
3682 (66.7)
2300 (41.6)
1622 (29.4)
138 (2.5)

374 (10.8)
808 (23.4)
1538 (44.5)
734 (21.3)
2322 (67.2)
1308 (37.9)
1027 (29.7)
111 (3.2)

7316 (35.2)
3570 (17.2)
8653 (41.6)
1241 (6.0)

974 (29.9)
571 (17.5)
1471 (45.2)
238 (7.3)

613
287
800
137

1652 (30.7)
879 (16.3)
2530 (47.0)
317 (5.9)

2144 (33.2)
932 (14.4)
2970 (46.0)
407 (6.3)

1983 (35.9)
750 (13.6)
2442 (44.2)
348 (6.3)

1433 (41.5)
435 (12.6)
1384 (40.1)
202 (5.8)

4 (2–6)
5 (3–6)

4 (2–6)
5 (3–7)

4 (2–6)
3 (1–5)

3 (2–5)
3 (1–5)

3 (2–5)
3 (1–5)

3 (2–5)
3 (1–5)

2 (1–4)

2 (0–4)

2 (0–3)

1 (0–3)

1 (0–2)

1 (0–2)

Smoking status, n (%)
Current
Former
Never
Unknown

Number of comorbidities, median (IQR)
Pre-index date
3 (1–5)
Post-index date
4 (2–6)
CCI at index date, median
(IQR)

2 (0–4)

(33.4)
(15.6)
(43.5)
(7.5)

CCI, Charlson Comorbidity Index; ICD, International Classification of Disease; IQR, interquartile range; PHQ-9, Patient Health Questionnaire-9; SD, standard deviation.

3.5. Treatment persistence

Table 2
Comorbidities before index date.
Pre-index comorbidities
(>10%)a, n (%)

ICD-9/10 population
(n=20,780)

PHQ-9 score ≥15
(n=8977)

Hypertension
Hyperlipidemia
Anxiety disorders
GI disorders (GERD, IBD, IBS)
Substance/alcohol use
disorder
Cancer
Sleeping disorders
Type 2 diabetes
Asthma
Coronary heart disease
Fibromyalgia

8864 (42.7)
8604 (41.4)
8169 (39.3)
7648 (36.8)
6771 (32.6)

3255 (36.3)
3837 (42.7)
4964 (55.3)
3680 (41.0)
3471 (38.7)

6136 (29.5)
5255 (25.3)
4088 (19.7)
3047 (14.7)
2700 (13.0)
2690 (12.9)

2460 (27.4)
3121 (34.8)
1482 (16.5)
1730 (19.3)
749 (8.3)b
1385 (15.4)

In a pooled analysis of patients with depression (ie, an ICD-9/10
and/or PHQ-9 diagnosis), within 6 months, ≥75% of patients dis
continued their first antidepressant, regardless of drug class, but dura
tion of persistence was highly variable for patients with an ICD-9/10
diagnosis (mean [SD] persistence, 197 [123] days) (Fig. 3). Median
(IQR) for treatment persistence was 206 (72–325) days in the ICD-9/10
cohort, and 155–160 (56–327) days in the PHQ-9 15–19 and ≥20 co
horts combined.
The number of comorbidities pre-index date and an ICD-9/10 diag
nosis were the only variables consistently associated with significantly
longer medication persistence across most antidepressant classes.
Advancing age was associated with shorter medication persistence for
all antidepressant classes. A higher number of medications prescribed
prior to index date was also associated with shorter persistence for se
lective serotonin reuptake inhibitors (SSRIs), serotonin-norepinephrine
reuptake inhibitors (SNRIs), and norepinephrine-dopamine reuptake
inhibitors (NDRIs), as was being married for SSRIs and tetracyclics, and
being a current smoker for NDRIs. Increased BMI also shortened
persistence with SNRIs, as did being a former smoker for other medi
cations. A PHQ-9 score ≥15 was not associated with any differences in
persistence (Supplementary Figs. 5–9).

GERD, gastroesophageal reflux disease; GI, gastrointestinal; IBD, inflammatory
bowel disease; IBS, irritable bowel syndrome; ICD, International Classification of
Disease; PHQ-9, Patient Health Questionnaire-9.
a
Comorbidity before index date or a minimum of 2 years prior to the index
date.
b
Less than 10% for PHQ-9 score ≥15.

4). Medication costs were significantly higher for male patients and
married patients, and increased with advancing age. Current smokers
had significantly lower medication costs in the 12 months following a
diagnosis of MDD.
An ICD-9/10 diagnosis of MDD and greater numbers of comorbidities
significantly increased the odds of HRU (ED, PCP, and BH visits)
(Table 3). A PHQ-9 score ≥15 was not significantly associated with
changes in ED visits.
Advancing age was associated with significantly lower odds of ED
and BH visits within 12 months of the index date, whereas a greater
number of medications prescribed prior to index date was associated
with greater odds of a PCP or ED visit (Table 3). A higher BMI increased
the odds of a BH visit within 12 months, but decreased the odds of an ED
or PCP visit (Table 3). Patients who were married had significantly
lower odds of an ED visit, and current or former smokers were less likely
to have a PCP visit (Table 3).

4. Discussion
Our study identified wide variability and gaps in the postdiagnosis
care of patients with MDD treated within an integrated healthcare sys
tem. Of note, patients diagnosed with depression in primary care had
substantial delays between antidepressant prescribing and subsequent
primary care visits. This is problematic, considering that more than
three-fourths of patients discontinued their first antidepressant therapy
within 6 months of prescribing. Furthermore, antidepressant switching
was common in patients with characteristics that may be predictive of a
greater engagement with the healthcare system, such as comorbidities,
which also may drive HRU and costs.
This is consistent with earlier reports of patients with MDD in the
United States receiving treatment in a primary care setting who often
received suboptimal or delayed treatment (Unützer and Park, 2012). In
addition, patients treated for depression in primary care may be less
380
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Fig. 2. Number of days to first BH visit following (A) the index date among patients with PCP visit during the study and (B) first antidepressant prescription among
patients with PCP visit and antidepressant prescription. BH, behavioral health; ICD, International Classification of Disease; PCP, primary care provider; PHQ-9,
Patient Health Questionnaire-9; SE, standard error.
Table 3
Logistic regression analysis of interactions between patients with MDD and healthcare providers within 12 months of index date.
Characteristic (N=17,834)

Age
Sex (male)
BMI
Married
Alcohol use
Smoking status
Current
Former
Never (reference)
Number of comorbidities pre-index date
Total number of all medications prescribed prior to
index date
ICD-9/10 diagnosis
PHQ-9 ≥15

ED visit

PCP visit

BH visit

Odds ratio (95% Wald
CI)

P value

Odds ratio (95% Wald
CI)

P value

Odds ratio (95% Wald
CI)

P value

0.983 (0.980–0.985)
1.122 (1.040–1.211)
0.990 (0.986–0.994)
0.878 (0.816–0.945)
0.851 (0.787–0.920)

<0.0001
0.0029
<0.0001
0.0005
<0.0001
0.3145
0.1285
0.6256

1.001 (0.998–1.004)
1.055 (0.954–1.168)
0.988 (0.983–0.994)
1.012 (0.916–1.119)
1.059 (0.954–1.176)

0.5628
0.2964
<0.0001
0.8148
0.2797
0.0013
0.0005
0.0314

0.972 (0.969–0.976)
0.973 (0.880–1.076)
1.006 (1.000–1.011)
1.039 (0.943–1.145)
0.973 (0.878–1.080)

<0.0001
0.5959
0.0357
0.4381
0.6095
0.0042
0.0022
0.8793

1.064 (0.982–1.153)
1.026 (0.924–1.140)
1.183 (1.161–1.205)
1.021 (1.014–1.029)
4.297 (3.985–4.633)
1.045 (0.965–1.132)

<0.0001
<0.0001

0.828 (0.744–0.920)
0.850 (0.733–0.986)
1.182 (1.148–1.217)
1.155 (1.136–1.174)

<0.0001
0.2824

0.751 (0.672–0.839)
1.132 (1.021–1.255)

<0.0001
<0.0001

0.848 (0.763–0.943)
1.011 (0.878–1.163)
1.089 (1.063–1.116)
1.009 (0.999–1.019)

<0.0001
0.0189

2.230 (2.013–2.471)
1.465 (1.325–1.621)

<0.0001
0.0853
<0.0001
<0.0001

BH, behavioral health; BMI, body mass index; CI, confidence interval; ED, emergency department; ICD, International Classification of Disease; MDD, major depressive
disorder; PCP, primary care provider; PHQ-9, Patient Health Questionnaire-9.
381
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Fig. 3. Treatment persistence by medication class among patients with MDD. Shaded areas represent 95% Hall and Wellner bands. MDD, major depressive disorder;
NDRI, norepinephrine-dopamine reuptake inhibitor; SNRI, serotonin-norepinephrine reuptake inhibitor; SSRI, selective serotonin reuptake inhibitor.

likely than patients treated in specialty care to receive treatment
consistent with existing guidelines (Unützer and Park, 2012). These gaps
may contribute to suboptimal management and potentially poorer
clinical outcomes (Kraus et al., 2019). For example, Ghio and colleagues
demonstrated that earlier treatment increased the probability of an
earlier response to treatment and final remission, as well as reducing
depression-related disability to a greater extent (Ghio et al., 2015).
Likewise, Bukh and colleagues reported that the probability of remission
was halved when treatment was delayed (Bukh et al., 2013).
Notably, patients diagnosed with MDD had a shorter time to first BH
visit following the index date if they were older (per year of age), had
comorbidities, had a high number of medications pre-index date, or had
an ICD-9/10 diagnosis. Earlier reports have suggested that older patients
may be aware of age-related factors that can lead to depression, such as
loneliness and boredom, which could in turn drive engagement with
healthcare professionals, reducing follow-up times (Stark et al., 2018).
In addition, patients who are older, have prior comorbidities, or have
polypharmacy may have higher HRU overall, suggesting that an earlier
BH visit may be a function of greater engagement with the healthcare
system rather than of necessarily being identified as being at higher risk
of poor outcomes (Glynn, 2011). Likewise, healthcare professionals may
be better acquainted with patients who have comorbidities, and
potentially more vigilant with the overall management of their health.
For example, knowledge of particular comorbidities, such as chronic
diseases, and being associated with an increased risk of depression
(Huang et al., 2010) may result in formal screening for depression
among patients with comorbidities and more active engagement with
and management of their medication. Screening of patients with
comorbidities for depression may also be a confounding factor that leads
to a formal ICD-9/10 code diagnosis rather than a PHQ-9 diagnosis,
explaining the similarities in adherence patterns between these pop
ulations. However, more research is required to better understand po
tential factors underlying this finding.
The finding that men attended BH visits earlier than women is also
consistent with previous reports of treatment patterns by sex. While
women have higher rates of hospitalization for depression, they are 18%
less likely than men to be hospitalized after presenting at an ED (Rost

et al., 2011). In addition, men are more likely to receive specialist
mental health services in addition to primary care support if they have
poorer perceived mental health status, comorbid anxiety, or
self-reported acceptability barriers, while these factors do not seem to
affect access to specialist services for women (Gagné et al., 2014). Men
also have been found to be more likely to be prescribed antidepressant
therapy (Lytsy et al., 2019), suggesting that the intensity of care received
by men with depression is often higher than that received by women
overall.
A number of other reasons may underpin the delay in follow-up PCP
and BH visits, with a key factor being barriers to patient scheduling of
future visits (Colorafi et al., 2017). In particular, financial issues,
availability of appointments, scheduling conflicts, perceived lack of
physician concern, stigma, and convenience of accessing treatment have
previously been identified as barriers to patients arranging follow-up
(Colorafi et al., 2017; Stark et al., 2018; Whitebird et al., 2013).
Furthermore, physicians have reported non–patient-related factors, such
as reimbursement, the scarcity of mental health resources, and poor
communication from healthcare service providers as barriers to earlier
follow-up for patients with depression (Whitebird et al., 2013).
Accordingly, if accessibility, affordability, and acceptability of care can
be enhanced, these may prove to be effective mechanisms for reducing
delays in subsequent visits from patients with depression (Colorafi et al.,
2017). Alternatively, it has been suggested that delays in treatment
could be due to patients’ perceived lack of need (Roberts et al., 2018).
Antidepressant medications were also frequently switched, suggesting
that treatment was not successful or well tolerated for a high proportion of
patients, although the rates of medication switching in this study were
consistent with those previously reported (Mars et al., 2017; Milea et al.,
2010; Wu et al., 2013). It is unclear from the data available whether these
switches were due to a lack of efficacy or tolerability, but it is reasonable
to suggest that the increased risk of switching in patients with comor
bidities may be linked to an interaction with their underlying conditions
and any associated treatments. Likewise, as noted in other studies,
treatment cost and HRU are generally more closely correlated with the
presence of comorbidities and number of medications received than
severity of depression (ie, higher PHQ-9 scores) (Robinson et al., 2016).
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The low persistence rates at 6 months observed in this study (45%–
54%) were consistent with rates noted in other studies (Bushnell et al.,
2016; Ereshefsky et al., 2010; Jung et al., 2015; Keyloun et al., 2017),
highlighting the need for earlier follow-up after a patient is diagnosed
with MDD to ensure appropriate therapy is offered in a timely manner.
The decreased rate of treatment persistence with age observed in this
study, which is contrary to other studies that specifically examined SSRI
or SNRI therapy (Bushnell et al., 2016; Wu et al., 2013), may also reflect
greater engagement of older versus younger patients with the primary
healthcare system, thereby facilitating earlier medication switching in
response to a lack of treatment efficacy or tolerability. Earlier follow-up
visits may also provide an opportunity for PCPs to support patients
receiving suboptimal treatment (Henke et al., 2009; Unützer and Park,
2012),
thus
potentially
preventing
premature
treatment
discontinuation.

5. Conclusions
Access to BH support is often highlighted as an area of unmet need
for patients with MDD, particularly because BH support is recommended
alongside antidepressant therapy in this patient population. Much
attention and resources are often focused on diagnosis, access to
healthcare, and therapeutic options, but a holistic approach may be
required to improve overall outcomes. Despite the availability of clinical
practice guidelines and algorithms to guide the care of patients with
MDD, their care in a large integrated healthcare system is highly vari
able, with gaps between current and optimal care. Our work highlights
potential targets for improving the care of patients with MDD. Opti
mizing the care of patients with MDD throughout their treatment
journey may improve outcomes and reduce HRU.
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We examined the care being provided for a large cohort of patients
with MDD utilizing both EHR and claims data. Although we observed
several notable trends, these data have several limitations. First, we
partly defined MDD based on ICD codes, which have been shown in
previous studies to not always accurately identify patients with MDD
(Fiest et al., 2014). To supplement this identification, we used PHQ-9
scores. Focusing on these discrete individual factors alone may not
lead to the call to action required to optimize care (Levis et al., 2019),
and despite efforts to have all patients screened for depression at every
primary care visit, compliance with this standard was not 100% during
the study period. These limitations mean that we may have missed or
misclassified incident cases of depression. Additionally, because patients
could have both a qualifying PHQ-9 score and an ICD diagnosis, we were
precluded from making robust direct comparisons between the 2 co
horts. Also, HRU, cost, and persistence data could be derived only from
the subset of patients with claims data available in the Geisinger Health
Insurance database, so detailed analysis of these outcomes was limited.
Furthermore, this study was performed in a US setting, which may limit
its generalizability. However, the findings are broadly similar to those
reported in international settings in terms of inconsistent follow-up after
a diagnosis of depression and poor adherence to treatment (Vuorilehto
et al., 2016).
4.2. Future directions
Additional studies are required to understand why follow-up is
delayed after patients are diagnosed with MDD, which may be particu
larly relevant for identifying and understanding the characteristics of
the subset of patients who appear to experience comparatively long
delays. For example, a short duration of treatment persistence and a long
delay before subsequent follow-up may be reflective of a depressive
episode rapidly resolving without any perceived need for further sup
port; alternatively, it may reflect the symptoms of MDD, making it more
difficult for patients to attend follow-up visits or persist with treatment.
Investigating whether delays in attending BH visits are a result of
delayed implementation of guideline-recommended treatment in a pri
mary care setting or the result of structural barriers to accessing treat
ment, such as a lack of appointment availability, could have an immense
impact on reducing variability among patients with MDD who are
managed in primary care. Such analyses also may identify opportunities
for BH specialists to improve communication with PCPs or raise aware
ness of the utility of BH visits for managing patients with depression.
Likewise, understanding the key differences between patients
receiving a PHQ-9 or ICD-9/10 diagnosis of depression and how that in
fluences treatment is of interest given the moderate overlap between the 2
systems (Löwe et al., 2004). This suggests that a substantial proportion of
patients with depression may not be diagnosed if relying on a single
screening instrument, especially if the definition of depression is rigid.
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